Hong Kong

With a rapidly ageing population and low birth rates, Hong Kong is one of many developed cities working to combat rises in healthcare burdens on an expected leap in the number of seniors.

To alleviate the burden on the public healthcare system, efforts are underway to improve disease awareness and shift public mindsets from reliance on treatment to preventive healthcare.

Roche Diagnostics has been a cornerstone of Hong Kong’s COVID-19 response. At the outset of the pandemic in January 2020, we supplied Hong Kong with its first batch of test kits for emergency screening and worked closely with the Department of Health and 7 Hospital Authority (HA) clusters to kick start their COVID-19 surveillance programme, delivering reagent supplies within 2 weeks.

Advancing Cervical Cancer testing

• To lower the incidence of cervical cancer and protect the lives of women, we have introduced self-testing as part of the standard cervical cancer screening process. This addresses the gaps in education and creates access to screening, particularly for those in underserved communities.

Ramping up Hong Kong’s COVID-19 testing capacity

• We have been a key player in supporting professional testing sites and home testing, in the process forging long-term partnerships with the government sectors and buttressing the city’s COVID-19 testing service.

A Green Office Overhaul

• To take proactive steps toward truly carbon-free operations, we overhauled our Hong Kong office in 2020 to reduce the consumption of materials and energy and contribute to sustainable development.